BioSpace News Archive

Mainz Biomed N.V. announced groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz Biomed’s ColoFuture and eAArly DETECT clinical trials evaluating the potential to integrate its portfolio of proprietary novel gene expression biomarkers into a next generation version of the Company’s colorectal cancer screening tool.

Envisagenics announced the publication in the journal Molecular Systems Biology of study results evaluating the company’s SpliceCore AI/ML platform in Triple Negative Breast Cancer.

TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 ASCO Annual Meeting taking place May 31-June 4, 2024 in Chicago, IL.

JTC Team (“JTC”), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor “What This Means” segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.

Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union.

4WEB Medical announced that it received regulatory clearance to market the newest addition to the company’s anterior lumbar implant portfolio, the Anterior Spine Truss System with Anchor Fixation (ASTS-AF).

Medical device innovator and worldwide leader in minimally invasive neurosurgery NICO Corporation is launching its latest product innovation at next week’s American Association of Neurosurgical Surgeons Annual Scientific Meeting in Chicago, Booth #825.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

Longeveron Inc. announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.